SpringWorks Therapeutics已向FDA提交了Mirdametinib用

快訊 · 07/01 18:30

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults With Nf1-Pn

SpringWorks Therapeutics已向FDA提交了Mirdametinib用於治療NF1-PN的新藥申請，適用於成人和兒童。